A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Radiation Oncology Residency Program Bookmark and Share

Radiation Oncology Residency Program

The City of Hope Radiation Oncology Residency Program is a four-year Accreditation Council for Graduate Medical Education (ACGME) accredited program which begins in the PGY-2 year. The overall goal of the program is to train physicians to be outstanding radiation oncologists and to provide graduates with a solid foundation in translational and clinical research. The program emphasizes preparation for careers in academic radiation oncology. The selection process gives preference to those applicants who show an aptitude for academic medicine and with an interest in teaching, research and the application of cutting-edge translational technologies to cancer care.

Training is provided in clinical radiation oncology, treatment planning, radiation physics, and radiobiology, equipping graduates to provide comprehensive patient care as practicing radiation oncologists either in academia or the private practice setting. Residents actively participate in the management of a diverse variety of patients, with progressively increasing responsibilities during later phases of the Program. The attending physicians and the resident physicians work as a team, with the resident assuming primary care responsibilities for patients under the attending’s supervision. The resident-attending teams evaluate and counsel new patients and provide treatment which includes radiotherapy simulation, treatment planning, and administration of irradiation. The resident physician follows the patient throughout treatment with attending supervision and subsequently in post-radiotherapy follow-up clinics.

Please refer to Resident Handbook for complete outline of Program Year Objectives.

The total complement of residents is four, with one resident currently being accepted per year into the program. The program participates in the National and Resident Matching Program, with applications processed through the Electronic Residency Application Service (ERAS) common application program. (Refer to Application Process for more information)

City of Hope continues to be on the forefront of the latest treatment technology and clinical research, providing residents with a rich and comprehensive training environment. As an NCI designated comprehensive cancer center and charter member of the NCCN, City of Hope provides an excellent environment for residency education. A major and extensive renovation is underway that will increase the clinical area to 29,000 square feet with 4 treatment vaults, 3 imaging suites, a new clinic area and expansion of treatment planning and physics work space. Two  Tomotherapy units, a Varian Trilogy and Varian IX will be installed. Multimodality functional tumor imaging will be a key part of the new center which will house MRI, PET/CT and CT units dedicated to treatment planning and treatment response assessment. In addition to these resources, radiation biology labs occupying a total of 4-5000 square feet currently house the labs of 4 NCI funded basic lab scientists. Finally an additional 8000 square feet is dedicated to an established radioimmunotherapy program with basic science laboratories and a radiopharmacy for the labeling of preclinical and clinical radiopharmaceuticals for tumor imaging and targeted tumor therapy.

Formal lectures cover radiation biology, physics, and clinical radiation oncology. clinical trial design, biostatistics, imaging (PET, SPECT, MRI,etc.), medical oncology and pediatric oncology. Multidisciplinary training will be emphasized. City of Hope has established fellowship programs in medical oncology, hematologic oncology, pathology, surgery, and urology. Ample interaction occurs through clinical conferences and tumor boards. Electives will be available with the other oncologic specialties.

Each resident will also be required to do an 8-12 month research rotation. He or she will select a lab or clinical research project to pursue, with the goal of publishing at least 2 manuscripts in peer-reviewed journals.

In accordance with the American Board of Radiology (ABR) for board eligibility, City of Hope requires successful completion of a clinical PGY1 year in the United States prior to commencing its four-year Radiation Oncology Residency Program.
 
 
Using leading edge technology, the Department of Radiation Oncology offers specialized services in external beam radiation therapy, radioactive seed implantation for prostate cancer, stereotactic radiosurgery and image guided intensity modulated radiation therapy. We also offer novel approaches to cancer therapy, such as radioimmunotherapy and helical tomotherapy. Through innovative laboratory and clinical research programs, we continue to investigate ways to further advance the efficacy and safety of radiation therapy.

Application Process

How to Apply
 
 
Application Checklist
 
  • ERAS application
  • Official college, graduate school and medical school transcripts
  • An official record of board scores (NBME, FLEX, USMLE, LMCC, COMLEX, VQE or FMGEMS).
  • A dean's letter and two other letters of recommendation.
  • A curriculum vita.
  • A personal statement.
 
 
Graduates from a medical school outside of the United States or Canada must submit a valid ECFMG certificate.

Applications for each academic year, which begins July 1, should be completed by December 1 of the previous calendar year. If you are selected for an interview, you will be invited to visit City of Hope for an interview with selected faculty. Interviews are conducted from late November through early February each year.
 
Contact
 
For further information, contact the program by phone or email:
 
Thalia Yaden
Residency Program Coordinator
City of Hope Department of Radiation Oncology
1500 E. Duarte Road, Duarte, CA 91010
Telephone: 626-301-8247, ext. 64163
radiationresident@coh.org
 

Faculty

In addition to caring for patients in their clinical practices, the City of Hope Department of Radiation Oncology faculty members are committed to teaching and facilitating the growth of medical knowledge.

Faculty members in the Department of Radiation Oncology include:
 
Radiation Oncologists:
 
  • Jeffrey Wong, M.D., FASTRO Chair
 
  • Eric Radany, M.D., Ph.D., Program Director
 
  • Richard Pezner, M.D.
 
  • Nayana Vora, M.D.
 
  • Yi-Jen Chen, M.D., Ph.D.
 
  • Khanh Nguyen, M.D.
 
  • Andrew Raubitschek, M.D. (Radioimmunotherapy)
 
 
 
Physicist:
 
  • Timothy Schultheiss, Ph.D. FACR, FAAPM, FASTRO, Director of Radiation Physics Cecil Staud, Ph.D.
 
  • An Liu, Ph.D.
 
  • Chun-Hui Han, Ph.D.
 
  • Sean Sun, M.S.
 
  • Lawrence Williams, Ph.D., FACR (Diagnostic Imaging)
 
  • James Bading, Ph.D. (Radioimmunotherapy)
 
 
 
Radiation Biology
 
  • Binghui Shen, Ph.D., Director, Radiation Biology
 
  • Jeremy Stark, Ph.D.
 
  • Fong-Fong Chu, Ph.D.
 

Facility and Department

City of Hope is recognized worldwide for its compassionate patient care, innovative science and translational research, which rapidly turns laboratory breakthroughs into promising new therapies. We are one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers nationwide and a founding member of the National Comprehensive Cancer Network. 
 
On our park-like campus just northeast of Los Angeles, City of Hope Helford Clinical Research Hospital brings groundbreaking research and compassionate care under one roof. It embodies our mission to deliver the newest, most promising therapies to patients without delay, while creating an environment that encourages open collaboration between physicians, caregivers and clinical researchers.
 
City of Hope Department of Radiation Oncology treats more than 900 patients each year. The department is equipped with state-of-the art technology, with facility renovation underway.  The department offers the full spectrum of radiation therapy modalities, including:
 
  • External beam radiation therapy with high-energy photons and electrons.
  • 3-D Conformal Radiation Therapy
  • IMRT -- Intensity Modulated Radiation Therapy
  • IGRT -- Image Guided Radiation Therapy
  • Stereotactic Radiosurgery
  • Total Body and Total Marrow Irradiation in conjunction with a Bone Marrow Transplant
  • Brachytherapy with LDR and HDR techniques
  • Treatment with Unsealed Sources, including targeted radiopharmaceuticals and radio-immunotherapy
 
 

Therapy Equipment 
 
  • Two Helical TomoTherapy – IGRT units
  • One Varian 21EX dual energy (6 MeV and 10 MeV), MLC linear accelerators with multiple electron capability and IMRT
  • One 6 MeV Varian linear accelerators.
  • Varian high dose-rate afterloader for interstitial and intracavitary implants.
  • Variety of low dose-rate sources available for implantation.
  • Ultrasound guided equipment for permanent prostate seed implants. Equipment to be added soon
  • One Varian Trilogy dual energy with CBCT/OBI and SRS/SRT capable.
  • One Varian iX dual energy accelerator with CBCT/OBI
 
Planning / Verification Equipment
 
  • Large bore CT-Simulation unit, dedicated for treatment planning
  • One Varian conventional simulator
  • Varian Eclipse Treatment Planning System
  • TomoTherapy Treatment Planning System
  • IMPAC Radiation Oncology Management System
 
Planning Equipment to be added soon
 
  • GE multi slice PET/CT simulator dedicated to planning and response assessment
  • GE 1.5T MRI dedicated to radiation oncology planning and response assessment
 
Conferences
Residents will be required to attend various radiation oncology conferences each week, as well as multidisciplinary conferences. An integrated, multidisciplinary approach to patient management is stressed. 
 
Multidisciplinary clinics or tumor boards occur in breast cancer; GU/prostate cancer, sarcomas, head and neck cancers; pediatric cancers; gynecological malignancies; gastrointestinal cancers; central nervous system cancers; and lymphomas. There is frequent interaction between all specialties which care for these patients including medical oncology, pediatric oncology, general surgery, head and neck surgery, the bone marrow transplantation service, pain service, neurosurgery, gynecological oncologists, thoracic surgery, and other ancillary services. 
 
Residents are a vital and important part of this multidisciplinary approach to the treatment of patients with cancer.
 

Radiation Oncology Residency Program

Radiation Oncology Residency Program

The City of Hope Radiation Oncology Residency Program is a four-year Accreditation Council for Graduate Medical Education (ACGME) accredited program which begins in the PGY-2 year. The overall goal of the program is to train physicians to be outstanding radiation oncologists and to provide graduates with a solid foundation in translational and clinical research. The program emphasizes preparation for careers in academic radiation oncology. The selection process gives preference to those applicants who show an aptitude for academic medicine and with an interest in teaching, research and the application of cutting-edge translational technologies to cancer care.

Training is provided in clinical radiation oncology, treatment planning, radiation physics, and radiobiology, equipping graduates to provide comprehensive patient care as practicing radiation oncologists either in academia or the private practice setting. Residents actively participate in the management of a diverse variety of patients, with progressively increasing responsibilities during later phases of the Program. The attending physicians and the resident physicians work as a team, with the resident assuming primary care responsibilities for patients under the attending’s supervision. The resident-attending teams evaluate and counsel new patients and provide treatment which includes radiotherapy simulation, treatment planning, and administration of irradiation. The resident physician follows the patient throughout treatment with attending supervision and subsequently in post-radiotherapy follow-up clinics.

Please refer to Resident Handbook for complete outline of Program Year Objectives.

The total complement of residents is four, with one resident currently being accepted per year into the program. The program participates in the National and Resident Matching Program, with applications processed through the Electronic Residency Application Service (ERAS) common application program. (Refer to Application Process for more information)

City of Hope continues to be on the forefront of the latest treatment technology and clinical research, providing residents with a rich and comprehensive training environment. As an NCI designated comprehensive cancer center and charter member of the NCCN, City of Hope provides an excellent environment for residency education. A major and extensive renovation is underway that will increase the clinical area to 29,000 square feet with 4 treatment vaults, 3 imaging suites, a new clinic area and expansion of treatment planning and physics work space. Two  Tomotherapy units, a Varian Trilogy and Varian IX will be installed. Multimodality functional tumor imaging will be a key part of the new center which will house MRI, PET/CT and CT units dedicated to treatment planning and treatment response assessment. In addition to these resources, radiation biology labs occupying a total of 4-5000 square feet currently house the labs of 4 NCI funded basic lab scientists. Finally an additional 8000 square feet is dedicated to an established radioimmunotherapy program with basic science laboratories and a radiopharmacy for the labeling of preclinical and clinical radiopharmaceuticals for tumor imaging and targeted tumor therapy.

Formal lectures cover radiation biology, physics, and clinical radiation oncology. clinical trial design, biostatistics, imaging (PET, SPECT, MRI,etc.), medical oncology and pediatric oncology. Multidisciplinary training will be emphasized. City of Hope has established fellowship programs in medical oncology, hematologic oncology, pathology, surgery, and urology. Ample interaction occurs through clinical conferences and tumor boards. Electives will be available with the other oncologic specialties.

Each resident will also be required to do an 8-12 month research rotation. He or she will select a lab or clinical research project to pursue, with the goal of publishing at least 2 manuscripts in peer-reviewed journals.

In accordance with the American Board of Radiology (ABR) for board eligibility, City of Hope requires successful completion of a clinical PGY1 year in the United States prior to commencing its four-year Radiation Oncology Residency Program.
 
 
Using leading edge technology, the Department of Radiation Oncology offers specialized services in external beam radiation therapy, radioactive seed implantation for prostate cancer, stereotactic radiosurgery and image guided intensity modulated radiation therapy. We also offer novel approaches to cancer therapy, such as radioimmunotherapy and helical tomotherapy. Through innovative laboratory and clinical research programs, we continue to investigate ways to further advance the efficacy and safety of radiation therapy.

Application Process

Application Process

How to Apply
 
 
Application Checklist
 
  • ERAS application
  • Official college, graduate school and medical school transcripts
  • An official record of board scores (NBME, FLEX, USMLE, LMCC, COMLEX, VQE or FMGEMS).
  • A dean's letter and two other letters of recommendation.
  • A curriculum vita.
  • A personal statement.
 
 
Graduates from a medical school outside of the United States or Canada must submit a valid ECFMG certificate.

Applications for each academic year, which begins July 1, should be completed by December 1 of the previous calendar year. If you are selected for an interview, you will be invited to visit City of Hope for an interview with selected faculty. Interviews are conducted from late November through early February each year.
 
Contact
 
For further information, contact the program by phone or email:
 
Thalia Yaden
Residency Program Coordinator
City of Hope Department of Radiation Oncology
1500 E. Duarte Road, Duarte, CA 91010
Telephone: 626-301-8247, ext. 64163
radiationresident@coh.org
 

Faculty

Faculty

In addition to caring for patients in their clinical practices, the City of Hope Department of Radiation Oncology faculty members are committed to teaching and facilitating the growth of medical knowledge.

Faculty members in the Department of Radiation Oncology include:
 
Radiation Oncologists:
 
  • Jeffrey Wong, M.D., FASTRO Chair
 
  • Eric Radany, M.D., Ph.D., Program Director
 
  • Richard Pezner, M.D.
 
  • Nayana Vora, M.D.
 
  • Yi-Jen Chen, M.D., Ph.D.
 
  • Khanh Nguyen, M.D.
 
  • Andrew Raubitschek, M.D. (Radioimmunotherapy)
 
 
 
Physicist:
 
  • Timothy Schultheiss, Ph.D. FACR, FAAPM, FASTRO, Director of Radiation Physics Cecil Staud, Ph.D.
 
  • An Liu, Ph.D.
 
  • Chun-Hui Han, Ph.D.
 
  • Sean Sun, M.S.
 
  • Lawrence Williams, Ph.D., FACR (Diagnostic Imaging)
 
  • James Bading, Ph.D. (Radioimmunotherapy)
 
 
 
Radiation Biology
 
  • Binghui Shen, Ph.D., Director, Radiation Biology
 
  • Jeremy Stark, Ph.D.
 
  • Fong-Fong Chu, Ph.D.
 

Facility and Department

Facility and Department

City of Hope is recognized worldwide for its compassionate patient care, innovative science and translational research, which rapidly turns laboratory breakthroughs into promising new therapies. We are one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers nationwide and a founding member of the National Comprehensive Cancer Network. 
 
On our park-like campus just northeast of Los Angeles, City of Hope Helford Clinical Research Hospital brings groundbreaking research and compassionate care under one roof. It embodies our mission to deliver the newest, most promising therapies to patients without delay, while creating an environment that encourages open collaboration between physicians, caregivers and clinical researchers.
 
City of Hope Department of Radiation Oncology treats more than 900 patients each year. The department is equipped with state-of-the art technology, with facility renovation underway.  The department offers the full spectrum of radiation therapy modalities, including:
 
  • External beam radiation therapy with high-energy photons and electrons.
  • 3-D Conformal Radiation Therapy
  • IMRT -- Intensity Modulated Radiation Therapy
  • IGRT -- Image Guided Radiation Therapy
  • Stereotactic Radiosurgery
  • Total Body and Total Marrow Irradiation in conjunction with a Bone Marrow Transplant
  • Brachytherapy with LDR and HDR techniques
  • Treatment with Unsealed Sources, including targeted radiopharmaceuticals and radio-immunotherapy
 
 

Therapy Equipment 
 
  • Two Helical TomoTherapy – IGRT units
  • One Varian 21EX dual energy (6 MeV and 10 MeV), MLC linear accelerators with multiple electron capability and IMRT
  • One 6 MeV Varian linear accelerators.
  • Varian high dose-rate afterloader for interstitial and intracavitary implants.
  • Variety of low dose-rate sources available for implantation.
  • Ultrasound guided equipment for permanent prostate seed implants. Equipment to be added soon
  • One Varian Trilogy dual energy with CBCT/OBI and SRS/SRT capable.
  • One Varian iX dual energy accelerator with CBCT/OBI
 
Planning / Verification Equipment
 
  • Large bore CT-Simulation unit, dedicated for treatment planning
  • One Varian conventional simulator
  • Varian Eclipse Treatment Planning System
  • TomoTherapy Treatment Planning System
  • IMPAC Radiation Oncology Management System
 
Planning Equipment to be added soon
 
  • GE multi slice PET/CT simulator dedicated to planning and response assessment
  • GE 1.5T MRI dedicated to radiation oncology planning and response assessment
 
Conferences
Residents will be required to attend various radiation oncology conferences each week, as well as multidisciplinary conferences. An integrated, multidisciplinary approach to patient management is stressed. 
 
Multidisciplinary clinics or tumor boards occur in breast cancer; GU/prostate cancer, sarcomas, head and neck cancers; pediatric cancers; gynecological malignancies; gastrointestinal cancers; central nervous system cancers; and lymphomas. There is frequent interaction between all specialties which care for these patients including medical oncology, pediatric oncology, general surgery, head and neck surgery, the bone marrow transplantation service, pain service, neurosurgery, gynecological oncologists, thoracic surgery, and other ancillary services. 
 
Residents are a vital and important part of this multidisciplinary approach to the treatment of patients with cancer.
 
Fellowships and Residencies
City of Hope offers a number of exciting fellowships and residencies in laboratory cancer and diabetes research, administration, clinical applications and other areas.

City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
Students and professionals at City of Hope can access a plethora of medical databases, scientific journals, course materials, special collections, and other useful resources at our 12,000 square foot Lee Graff Library.
City of Hope has a long-standing commitment to Continuing Medical Education (CME), sharing advances in cancer research and treatment with the health-care community through CME courses such as conferences, symposia and other on and off campus CME opportunities for medical professionals.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.


NEWS & UPDATES
  • We’ve all heard the mantra: Cancer screening saves lives. And it does, especially with colorectal cancer. Regular colonoscopies have been proven to reduce the risk of colorectal cancer death by up to 70 percent. Screening for colorectal cancer using the even simpler fecal occult blood tests has been found to re...
  • Pick up any biotech industry report and you’re guaranteed to come across one term repeatedly – CAR-T therapy. A fierce competition is now underway to bring CAR-T treatments to market – several companies (Juno, Novartis, Kite and Cellectis, to name a few) have major stakes in the race. I’ve found the CAR-T buzz ...
  • Patients undergoing treatment at City of Hope know they will be receiving the best medical care available, that their treatment will be delivered with compassion and that their care will extend to their families. “When we treat a patient here, we treat a family,” says Jo Ann S. Namm, child life manager and spec...
  • Did you know that colorectal cancer equally affects men and women? Or that it’s the third-leading cause of cancer death in the U.S.? Most important, did you know that colorectal cancer is very treatable and highly curable if detected early? If you didn’t know these facts, it’s time to learn. M...
  • To celebrate the beginning of Lunar New  Year 2015, City of Hope honored not just a new lunar calendar, but also the diversity of the community it serves. On Jan. 21, as tens of thousands of people celebrated Lunar New Year (and the arrival of the Year of the Ram) in the streets of L.A.’s Chinatown, City of [&#...
  • The breakthroughs that have revolutionized cancer treatment, transforming cancer in many cases to a very manageable and even curable disease, started out as just ideas. “I will often tell patients there’s no therapy we’re using to help them that wasn’t derived from somebody’s idea in some laboratory, working la...
  • The prostate cancer screening debate, at least as it relates to regular assessment of prostate specific antigen levels, is far from over. The U.S. Preventive Services Task Force recommended against routine PSA screening for prostate cancer in 2012, maintaining that the routine use of the PSA blood test does mor...
  • Cancer patients should get more than medical treatment. They should get comprehensive, evidence-based care that addresses their full range of needs. That kind of patient-focused care is City of Hope’s specialty. Under the guidance of Dawn Gross, M.D., Ph.D., the new Arthur M. Coppola Family Chair in Suppo...
  • Think twice before tossing out those hormone replacement pills. Although a new Lancet study suggests that hormone replacement therapy could increase a woman’s risk of ovarian cancer, a City of Hope expert urges women to keep this news in perspective. Hormone replacement therapy is prescribed to help allev...
  • Don’t know what to take, or send, that friend of yours in the hospital? Try a paper plate — filled not with cookies or sweets, but an image of yourself. Ilana Massi, currently undergoing treatment at City of Hope for acute myeloid leukemia, can vouch for the power of such a gift. She’s surrounded herself [̷...
  • With precision medicine now a national priority, City of Hope has joined a novel research partnership designed to further understanding of cancer at the molecular level, ultimately leading to more targeted cancer treatments. The Oncology Research Information Exchange Network, or ORIEN, is the world’s larg...
  • The spinal cord is an integral part of the human body, connecting the brain to everything else. So when a tumor grows on the spine, any messages that the brain tries to send to the rest of the body are interrupted, making everyday tasks — such as walking — more difficult. This year an estimated 22,850 […]
  • Each year, thousands of patients with hematologic malignancies undergo allogeneic stem cell transplantation (that is, they receive a donor’s stem cells), offering them a chance at cure. Graft-versus-host disease is a potentially deadly complication of this therapy and occurs in approximately 25 to 60 perc...
  • Bertram Yuh, M.D., assistant clinical professor in the Division of Urology and Urologic Oncology at City of Hope, offers his perspective on the benefits of surgery for aggressive prostate cancer. For men walking out of the doctor’s office after a diagnosis of cancer, the reality can hit like a ton of bricks. Th...
  • Although many Hispanic women face a high risk of mutations in the BRCA1 and BRCA2 genes – increasing their risk of breast and ovarian cancer – screenings for these mutations can be prohibitively expensive in Mexico and other Latin American countries. As a result, too many women don’t get the information t...